PRL and hyperpituitarism: The precise characterization of one or more VAC extract molecules able to therapeutically impact on the PRL levels and proving that such VAC component or components are effective and safe in vivo is, in our opinion, the only option for possibly considering the use of VAC, in the form of specific component or components, for the treatment of hyperprolactinaemia.